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Background In clinical practice or trials on hand eczema the severity of this disease
can be ‘measured’ in different ways: by means of a physician-rated clinical sever-
ity score, a patient-rated clinical severity score or by an indicator of the burden
of disease. We assume that the patient-rated severity score corresponds more
with the (change in) burden of disease than with the physician-rated severity
score.
Objectives To demonstrate how physicians and patients differ in their assessment of
the severity of hand eczema as seen in a physician-rated severity score, patient-
rated severity score and a burden of disease questionnaire.
Methods We used data from an open-label randomized controlled trial which was
set up in two university hospital dermatology departments in the Netherlands,
specializing in hand eczema. One hundred and fifty-eight patients with moderate
to severe chronic hand eczema were included. The main outcome measures were
the physician-rated severity score, based on five visible aspects of hand eczema
(desquamation, erythema, vesicles, infiltration, fissures), the patient-rated severity
score (a self-rating scale), a burden of disease questionnaire (the Dermatology
Life Quality Index, DLQI) and the correlations between these parameters, both at
inclusion and over time.
Results Only desquamation and infiltration were significantly correlated with
patient-rated severity score. Patient-rated severity score correlated with seven of
10 DLQI items, but it did not correlate with the items regarding influence on
clothes worn, impairment of sporting activities, and problems associated with
treatment of the skin. The majority of patients showed improvement in all
parameters after treatment. However, the improvement in patient-rated severity
score was not clearly correlated with changes in physician-rated severity score.
Except for DLQI item 1 (itch, soreness, pain, stinging), none of the changes in
burden of disease was correlated with changes in patient-rated severity score. For
each DLQI item, change over time correlated weakly with decreases in several,
but not all, components of the physician-rated severity score.
Conclusions Disease severity can be expressed by different scores; these scores are
not clearly correlated, and measure different aspects. Patient satisfaction is not
guaranteed when treatment is focused solely on the visible aspects of hand
eczema. Instead, burden of disease has a greater impact.
We often ‘measure’ hand eczema for research and in clinical
practice. This can be done with respect to its clinical severity
and with respect to its impact on the patient’s quality of life,
or burden of disease. Both the physician and the patient may
assess the severity of the hand eczema. The physician is limited
to assessing the clinical severity, whereas the patient may also
indicate its consequences for specific aspects of life, which
reflect his or her perception of the burden of the disease.
We will demonstrate how physicians and patients differ in
their assessment of severity of hand eczema. In particular, we
assume that the patient’s assessment of the severity of hand
eczema corresponds more with the (change in) consequences
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of the disease in several aspects of life than with the phys-
ician’s judgement.
The results will provide more insight into the discrepancies
between the patient’s and the physician’s assessment of sever-
ity, as is so often encountered in daily practice. This may also
help the physician to focus on those aspects of hand eczema
that hinder the patient most, and help in explaining to the
patient that medical therapy alone does not always alleviate all
the consequences of hand eczema. Therefore, psychosocial
counselling may also be necessary.
Patients and methods
Study population
The study was conducted within the framework of a random-
ized controlled trial which compared two types of psoralen
plus ultraviolet A treatment.1 The study population consisted
of consecutive patients with chronic hand eczema attending
two dermatology outpatient clinics. They were assessed for eli-
gibility for inclusion into this trial. Inclusion criteria were:
chronic bilateral or unilateral hand eczema of at least 1 year’s
duration, at least two relapses or more than three consecutive
weeks with visible signs in the last 3 months, and a severity
score of at least 6 (sum of scores of both hands), as rated by
a dermatologist.2 In total, 196 patients were considered to be
eligible for this trial. Twenty-four patients did not meet the
inclusion criteria, and 14 refused to participate. The remaining
158 patients gave written informed consent.
All patients were seen over a 10-week period. Assessments
of severity and burden of disease were done at randomization
(T1) and after the 10-week treatment period (T2).
Data collection
The severity of each patient’s hand eczema was assessed by a
dermatologist using a scoring system based on the following
five visible aspects of hand eczema: erythema, desquamation,
vesiculation, infiltration and fissures. This is a modification of
the severity score reported by Rose´n et al.2 Each item was
scored as 0, 1, 2 or 3 for each hand separately (the higher the
score, the more severe is the disease). The final severity score
was calculated by averaging the scores of both hands and
rounding to a whole number. Itch and pain, items included in
the scoring system as described by Rose´n et al.,2 were not
included because these cannot be assessed objectively by a
physician. Changes in the physician-rated severity score were
calculated by deducting the score at T1 from the score at T2,
resulting in a negative number when there was improvement.
The patient’s perception of the severity of the hand eczema
(patient-rated severity score) was established with a self-rating
scale from 1 to 10: 1 for very severe (‘bad’) and 10 for no
signs and symptoms (‘good’). This kind of rating is com-
monly used in the Netherlands, analogous to a report mark.
Changes in the patient-rated severity score were calculated by
deducting the score at T1 from the score at T2, resulting in a
positive number when there was improvement.
As there is no questionnaire for specifically measuring the
burden of the disease in patients with chronic hand eczema,
we used the Dermatology Life Quality Index (DLQI).3 The
DLQI consists of 10 questions on several different aspects of a
patient’s life that may be affected by a skin disease. We
assumed that the DLQI would also cover essential aspects of
hand eczema (see Table 1). Each item was scored as 0, 1, 2
or 3, where higher scores indicated more problems. Changes
in the burden of disease were calculated by deducting the
DLQI score at T1 from the score at T2, resulting in a negative
numbers when there was improvement.
Statistical analysis
The mean and SD were calculated for all variables. As the
physician-rated severity score and the DLQI items consist of
only four categories, a distribution of frequencies at T1 is also
shown.
The physician-rated severity score and DLQI items are con-
sidered to measure at an ordinal level. Therefore, the relation-
ship between these items and the patient-rated severity score
Table 1 Dermatology Life Quality Index3
Item Question
1 Over the last week, how itchy, sore, painful or stinging has your skin been?
2 Over the last week, how embarrassed or self-conscious have you been because of your skin?
3 Over the last week, how much has your skin interfered with you going shopping or looking after your home or garden?
4 Over the last week, how much has your skin influenced the clothes you wear?
5 Over the last week, how much has your skin affected any social or leisure activities?
6 Over the last week, how much has your skin made it difficult for you to do any sport?
7 Over the last week, has your skin prevented you from working or studying?
If ‘No’, over the last week how much has your skin been a problem at work or studying?
8 Over the last week, how much has your skin created problems with your partner or any of your close friends or relatives?
9 Over the last week, how much has your skin caused any sexual difficulties?
10 Over the last week, how much of a problem has the treatment for your skin been, for example by making your home messy,
or by taking up time?
Patients were instructed to give one answer for each question. They could choose from: very much, a lot, a little, not at all or not relevant.
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is expressed by means of Spearman’s rank correlations. Multi-
variable methods were considered but, in the absence of
known confounders, were deemed unhelpful.
To describe the change over time in the physician-rated
severity scores and in the DLQI items in a meaningful way,
the percentage of patients who improved is given, whereby
only patients with a score > 0 at T1 are considered (i.e. only
the patients who have a problem in connection with this spe-
cific item).
We calculated the Spearman’s rank correlations between, re-
spectively, the patient-rated severity scores, the physician-rated
severity scores and the DLQI. We did the same for the changes
over time for the severity parameters. A correlation of 0Æ10 is
considered weak and 0Æ30 moderate. P < 0Æ05 was considered
statistically significant.
Results
Physician-rated severity score and patient-rated severity
score at randomization
During an 18-month period, 158 patients, 88 men (56%) and
70 women (44%) (mean ± SD age 42 ± 14 years, range 18–
70), were enrolled into this study.
At T1, desquamation and erythema were scored most fre-
quently (in 99% of the patients) and had the highest scores of
the five aspects of the physician-rated severity score (a mean
of 1Æ9) (Table 2).
Only desquamation and infiltration were significantly cor-
related with the patient-rated severity score (r ¼ )0Æ20). The
mean patient-rated severity scores of the separate judgements
by the physician are also shown in Table 2. Desquamation,
erythema and infiltration showed a weak linear relationship
between the physician-rated severity score and the patient-
rated severity score.
Patients assessed the severity of their hand eczema with a
mean ± SD score of 4Æ4 ± 1Æ6, which indicated much discon-
tent (a lower score indicates more severe disease). Only 20%
of the patients scored 6 or higher.
Burden of disease and patient-rated severity score at
randomization
The mean ± SD total DLQI score at T1 was 9Æ7 ± 6Æ6. The
items that revealed the highest impact on the burden of dis-
ease were DLQI items 1 and 3, measuring pain/itch and skin
problems preventing shopping or looking after the home or
garden (see Table 3).
With the exception of the items regarding the influence on
clothes worn, impairment of sporting activities and problems
associated with treatment of the skin (i.e. DLQI items 4, 6
and 10), all other DLQI items were significantly related to the
patient-rated severity score. The highest correlations were
noted for the items regarding itch/soreness/pain/stinging,
going shopping or looking after the home or garden and
impairment of work or study (DLQI items 1, 3 and 7). Especi-
ally those patients who rated the burden of disease on a par-
ticular aspect as ‘very much’ appeared to grade their disease as
more severe, i.e. scored higher in the patient-rated severity
scale.
Changes over time
A decrease in the severity and the burden of disease was to be
expected because all patients were treated for their hand
eczema between T1 and T2. Many patients did not have all
the symptoms that were characteristic for hand eczema. More-
over, not all patients indicated their hand eczema to be a bur-
den for all 10 different aspects of life. Therefore, when
describing changes between T1 and T2, and the relationships
between changes in indicators, we have chosen to describe
the percentages of patients who had the possibility to improve
their score and to describe the percentage of that group who
did indeed improve their score (Tables 4 and 5). Of the 158
patients enrolled at the start (T1), 33 dropped out during the
treatment period.
Most of the patients who had a particular problem as
assessed by the physician (i.e. who had symptoms of desqua-
mation, erythema, vesicles, infiltration or fissures) of showed
Table 2 Descriptives of components of the physician-rated severity score at randomization
Mean SD 0 1 2 3 Correlationa
Desquamation 1Æ9 0Æ7 1% 23% 62% 15% )0Æ20*
Mean PRS – 4Æ8 4Æ4 3Æ8
Erythema 1Æ9 0Æ6 1% 23% 65% 11% )0Æ10
Mean PRS – 4Æ7 4Æ3 4Æ2
Vesicles 0Æ6 0Æ8 54% 30% 15% 1% 0Æ10
Mean PRS 4Æ3 4Æ4 4Æ8 4Æ0
Infiltration 0Æ9 0Æ7 28% 55% 15% 3% )0Æ20*
Mean PRS 4Æ7 4Æ4 3Æ7 3Æ3
Fissures 0Æ9 0Æ9 39% 36% 22% 3% )0Æ09
Mean PRS 4Æ5 4Æ4 4Æ0 4Æ4
PRS, patient-rated severity score. aCorrelation between patient-rated severity score and the corresponding aspect of the physician-rated score
of hand eczema (Spearman’s rank correlation). *P < 0Æ05.
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an improvement ranging from 56% for erythema to 78% for
fissures (Table 4).
The total patient group rated the severity of their hand
eczema (patient-rated severity score) a mean ± SD of
1Æ1 ± 1Æ8 points higher at T2. This more positive judgement
was, however, not related to the changes in the physician-
rated severity score.
Of the patients who reported problems in various aspects of
life caused by hand eczema (i.e. who scored ‘a little’/‘a lot’/
‘very much’ on the DLQI items), the majority experienced
improvement, ranging from 56% for itch and pain (DLQI
item 1) to 77% among those who reported problems with
treatment of their skin (DLQI item 10). With the exception of
item 1 (r ¼ )0Æ22), however, none of these changes in bur-
den of disease was significantly related to a change in patient-
rated severity score (Table 5).
In Table 6 the relationships between changes in physician-
rated severity score and changes in the burden of disease are
presented. For each DLQI item, the change over time is correl-
ated with a decrease in a component of the physician-rated
severity score. Overall, both indicators are only weakly related.
In fact, correlations of more than 0Æ40 were found only
between a decrease in erythema and an improvement of pain/
itch, and between a decrease in infiltration and a change in
social or leisure activities.
Table 3 Descriptives of the Dermatology Life Quality Index (DLQI) at randomization
Mean SD 0 1 2 3 Correlationa
DLQI 1 2Æ1 0Æ9 5% 19% 42% 35% )0Æ36*
Mean PRS 4Æ5 4Æ8 4Æ9 3Æ4
DLQI 2 1Æ2 1Æ1 35% 30% 18% 18% )0Æ27*
Mean PRS 4Æ8 4Æ5 4Æ0 3Æ5
DLQI 3 1Æ6 1Æ1 22% 25% 29% 24% )0Æ34*
Mean PRS 4Æ9 4Æ8 4Æ2 3Æ5
DLQI 4 0Æ5 0Æ8 68% 18% 11% 3% )0Æ11
Mean PRS 4Æ5 3Æ8 4Æ6 3Æ2
DLQI 5 1Æ2 1Æ1 32% 30% 21% 17% )0Æ23*
Mean PRS 4Æ6 4Æ9 3Æ9 3Æ4
DLQI 6 0Æ9 1Æ2 56% 16% 11% 18% )0Æ10
Mean PRS 4Æ5 4Æ9 4Æ3 3Æ7
DLQI 7 0Æ7 1Æ1 67% 11% 7% 15% )0Æ32*
Mean PRS 4Æ7 4Æ1 3Æ7 3Æ4
DLQI 8 0Æ4 0Æ8 77% 12% 5% 6% )0Æ21*
Mean PRS 4Æ5 4Æ5 2Æ7 3Æ3
DLQI 9 0Æ5 0Æ9 75% 11% 9% 6% )0Æ20*
Mean PRS 4Æ5 4Æ3 3Æ9 3Æ1
DLQI 10 0Æ8 1Æ0 49% 26% 18% 6% )0Æ03
Mean PRS 4Æ3 4Æ7 4Æ5 2Æ5
PRS, patient-rated severity score. aCorrelation between patient-rated severity score and the corresponding DLQI item (Spearman’s rank correl-
ation). *P < 0Æ05.
Table 4 Changes in components of the physician-rated severity score












Desquamation 100 67 )0Æ13
Erythema 100 56 )0Æ06
Vesicles 45 69 0Æ04
Infiltration 74 67 )0Æ09
Fissures 59 78 )0Æ10
T1, at randomization; T2, after the 10-week treatment period.
Number of patients ¼ 123.













DLQI 1 94 56 )0Æ22*
DLQI 2 65 70 )0Æ19
DLQI 3 79 66 )0Æ16
DLQI 4 33 71 0Æ16
DLQI 5 66 72 )0Æ04
DLQI 6 44 76 )0Æ00
DLQI 7 37 67 )0Æ06
DLQI 8 24 72 )0Æ04
DLQI 9 24 68 0Æ05
DLQI 10 51 77 )0Æ06
T1, at randomization; T2, after the 10-week treatment period.
Number of patients ¼ 107. *P ¼ 0Æ029.
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Discussion
Patients may indicate the burden of their disease for 10 differ-
ent DLQI items. The mean DLQI was 9Æ7. Hutchings et al.4
reported an overview of mean DLQI scores for 15 dermatoses.
Only urticaria with delayed pressure urticaria (DLQI 12Æ9) and
atopic eczema (DLQI 12Æ5) had a higher mean score.5,6 Dis-
eases such as psoriasis (8Æ9) and hair loss (8Æ3), which are
well known for their burden of disease, had lower scores.3,7
This illustrates the high impact of hand eczema on the
patient’s well-being. It should, however, be kept in mind that
our study did not include patients with mild hand eczema.
There was a weak relationship between physician-rated
severity score and patient-rated severity score at T1. In gen-
eral, an improvement in visible aspects of hand eczema did
not lead to an improvement in the patient’s assessment. Two
different physician-rated severity scores have recently been
validated; unfortunately, these instruments were not yet avail-
able at the time of our study.8,9
We noted a weak to moderate relationship between patient-
rated severity score and the burden of disease; however, a cor-
relation coefficient of 0Æ36 (such as between DLQI item 1 and
patient-rated severity) implies that only 13% of the variability
can be explained by the correlation. An improvement in the
burden of disease did not correspond to an improvement in
patient-rated severity score.
Finally, an improvement in physician-rated severity score
was weakly to moderately related to improvement in the
burden of disease. This relationship was more pronounced
for erythema with itch/soreness/pain (DLQI item 1), and
for infiltration with social/leisure activities (DLQI item 5),
although the correlation explains only up to 23% of the
variability.
The high drop-out rate of 21% may be considered a poten-
tial source of bias. There was, however, no difference between
the drop-outs and the remaining participants with regard to
physician-rated severity score at T1 or change between T1 and
T2.1 Furthermore, the physician-rated severity score was cal-
culated by taking the mean score of the right and the left
hand. Thus, the most severely affected or dominant hand was
not taken into account.
We asked ourselves to what extent the DLQI measured
problems that were solely attributable to hand eczema, a ques-
tion that may also be posed for burden of disease question-
naires other than the DLQI. To date, only the DLQI has been
validated for patients with hand eczema.10
Our findings are similar to those of Jayaprakasam et al.,11
who reported that the interpretation of burden of disease from
disease severity is unreliable. They had, however, only looked
at physician-rated severity and not at patient-rated severity. In
addition, the study was not limited to hand eczema, or to
another specific skin disease. Heydendael et al.12 also reported
no significant relationship between disease severity and burden
of disease.
Cvetkovski et al.13 described how the patients’ self-assess-
ment of their hand eczema was significantly more severe than
the dermatologist’s rating, who used a standardized severity
assessment tool. This resulted in a very low positive predictive
value and a high negative predictive value of the patient’s self-
assessment. This limited relationship between patients’ and
physicians’ opinions is in line with our own findings. The
same authors report a DLQI of 5Æ5 among hand eczema
patients in a paper that examines a link between depression
and the separate DLQI items; their lower mean score com-
pared with ours may be explained by the fact that almost a
third had minimal severity.14
These findings are important to the dermatologist. When
treatment is focused solely on the visible aspects of hand
eczema, patients’ satisfaction with their skin condition is not
guaranteed. Alleviation of burden of disease has a higher
impact on patients’ assessment of their hand eczema. Although
medical treatment of some visible aspects of chronic hand
eczema has to some extent an impact on the burden of dis-
ease, patients may also need counselling and support by other
professionals such as, for example, specialized nurses, to cope
with their disease.
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